- Home
- OLMA vs HQL Comparison
OLMA vs HQL Comparison
Compare OLMA & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLMA
- HQL
- Stock Information
- Founded
- OLMA 2006
- HQL 1992
- Country
- OLMA United States
- HQL United States
- Employees
- OLMA N/A
- HQL N/A
- Industry
- OLMA Biotechnology: Pharmaceutical Preparations
- HQL Investment Managers
- Sector
- OLMA Health Care
- HQL Finance
- Exchange
- OLMA Nasdaq
- HQL Nasdaq
- Market Cap
- OLMA 378.9M
- HQL 378.8M
- IPO Year
- OLMA 2020
- HQL N/A
- Fundamental
- Price
- OLMA $7.89
- HQL $13.92
- Analyst Decision
- OLMA Strong Buy
- HQL
- Analyst Count
- OLMA 5
- HQL 0
- Target Price
- OLMA $24.00
- HQL N/A
- AVG Volume (30 Days)
- OLMA 1.0M
- HQL 120.9K
- Earning Date
- OLMA 11-11-2025
- HQL 01-01-0001
- Dividend Yield
- OLMA N/A
- HQL 11.56%
- EPS Growth
- OLMA N/A
- HQL N/A
- EPS
- OLMA N/A
- HQL 0.79
- Revenue
- OLMA N/A
- HQL N/A
- Revenue This Year
- OLMA N/A
- HQL N/A
- Revenue Next Year
- OLMA N/A
- HQL N/A
- P/E Ratio
- OLMA N/A
- HQL $17.08
- Revenue Growth
- OLMA N/A
- HQL N/A
- 52 Week Low
- OLMA $2.86
- HQL $11.34
- 52 Week High
- OLMA $13.93
- HQL $14.37
- Technical
- Relative Strength Index (RSI)
- OLMA 66.97
- HQL 51.80
- Support Level
- OLMA $7.49
- HQL N/A
- Resistance Level
- OLMA $8.25
- HQL $14.30
- Average True Range (ATR)
- OLMA 0.66
- HQL 0.16
- MACD
- OLMA 0.12
- HQL -0.55
- Stochastic Oscillator
- OLMA 80.06
- HQL 96.80
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.